Comparable stake leader
GLAZER CAPITAL, LLC
SEC ownership of Astria Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001454789.
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
5/7
Latest evidence
31 Dec 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GLAZER CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
5 of 7
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GLAZER CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001454789
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Astria Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GLAZER CAPITAL, LLC
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
5/7
Latest evidence
31 Dec 2025
13D/G
3/4/5
Lead comparable stake: 6.6%
2 rows are not safely comparable across share classes.
13D/G row: GLAZER CAPITAL, LLC
Quick read
GLAZER CAPITAL, LLC leads the comparable SEC ownership view at 6.6%.
5 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GLAZER CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
GLAZER CAPITAL, LLC
6.6%
Venrock Healthcare Capital Partne...
4.4%
Fairmount Funds Management LLC
4%
FMR LLC
2.2%
INTEGRATED CORE STRATEGIES (US) LLC
0.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-7 of 7 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC |
13D/G
|
6.6%
|
$48,032,679
3,776,154 shares
|
+$7,898,535 | 31 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
4.4%
|
$12,704,489
2,457,348 shares
|
$0 | 31 Dec 2024 |
| Fairmount Funds Management LLC |
13D/G
|
4%
|
$17,304,917
2,377,049 shares
|
-$25,421,673 | 14 Oct 2025 |
| FMR LLC |
13D/G
|
2.2%
|
$9,112,857
1,251,766 shares
|
-$28,407,637 | 31 Oct 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
0.4%
|
$1,616,895
222,101 shares
|
-$19,770,311 | 14 Oct 2025 |
| PERCEPTIVE ADVISORS LLC |
3/4/5
Director
|
—
mixed-class rows
|
$67,172,360
6,140,223 shares
mixed-class rows
|
— | 01 Feb 2024 |
| Andrew John Nichols |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
—
55,000 shares
|
— | 01 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Astria Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
PERCEPTIVE ADVISORS LLC
Net 12M change
$0
Latest report
23 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director | $67,172,360 | Filing P/S | 01 Feb 2024 | ||
| Jonathan Violin | Director | $0 | Mixed | 23 Jan 2026 | ||
| Jill C. Milne | CEO and President, Director | $0 | Mixed | 23 Jan 2026 | ||
| Andrew Komjathy | Chief Commercial Officer | $0 | Mixed | 23 Jan 2026 | ||
| Fred P. Callori | Director | Mixed | 23 Jan 2026 | |||
| Noah Clauser | Chief Financial Officer | Mixed | 23 Jan 2026 | |||
| Hugh M. Cole | Director | Mixed | 23 Jan 2026 | |||
| Benjamin Harshbarger | Chief Legal Officer | Mixed | 23 Jan 2026 | |||
| Andrea Matthews | Chief Business Officer | Mixed | 23 Jan 2026 | |||
| Christopher Morabito | Chief Medical Officer | Mixed | 23 Jan 2026 | |||
| Gregg A. Lapointe | Director | Mixed | 23 Jan 2026 | |||
| Michael D. Kishbauch | Director | Mixed | 23 Jan 2026 | |||
| Andrew John Nichols | Chief Scientific Officer | Mixed | 01 Mar 2022 | |||
| Kenneth Bate | Director | Mixed | 23 Jan 2026 | |||
| Sunil Agarwal | Director | Mixed | 23 Jan 2026 | |||
| Beck Joanne T. | Director | Mixed | 23 Jan 2026 |
Recent insider transactions for Astria Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jonathan Violin | ATXS | Common Stock | Disposed to Issuer | -100% | -263,321 | 0 | 23 Jan 2026 | Direct | ||
| Jonathan Violin | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | 77,249 | 0 | 23 Jan 2026 | Direct | |||
| Christopher Morabito | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -342,500 | 0 | 23 Jan 2026 | Direct | ||
| Jill C. Milne | ATXS | Common Stock | Disposed to Issuer | -100% | -4,377 | 0 | 23 Jan 2026 | Direct | ||
| Jill C. Milne | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -956,000 | 0 | 23 Jan 2026 | Direct | ||
| Andrea Matthews | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -315,312 | 0 | 23 Jan 2026 | Direct | ||
| Andrew Komjathy | ATXS | Common Stock | Disposed to Issuer | -100% | -90 | 0 | 23 Jan 2026 | See footnote | ||
| Andrew Komjathy | ATXS | Common Stock | Disposed to Issuer | -100% | -10 | 0 | 23 Jan 2026 | Direct | ||
| Andrew Komjathy | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -280,000 | 0 | 23 Jan 2026 | Direct | ||
| Benjamin Harshbarger | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -350,833 | 0 | 23 Jan 2026 | Direct | ||
| Hugh M. Cole | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -79,749 | 0 | 23 Jan 2026 | Direct | ||
| Noah Clauser | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -317,500 | 0 | 23 Jan 2026 | Direct | ||
| Fred Callori | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -77,249 | 0 | 23 Jan 2026 | Direct | ||
| Beck Joanne T. | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -79,749 | 0 | 23 Jan 2026 | Direct | ||
| Sunil Agarwal | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -54,750 | 0 | 23 Jan 2026 | Direct | ||
| Anthony Gregg Lapointe | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -79,749 | 0 | 23 Jan 2026 | Direct | ||
| Kenneth Bate | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -79,749 | 0 | 23 Jan 2026 | Direct | ||
| Michael D. Kishbauch | ATXS | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -79,749 | 0 | 23 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.